-transparent.png){kind=logo}
Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil against various tumors was examined. Therapeutic ratio (ILSmax/ILS30) in L-1210 system was 4.5 by oral administration, while those of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil were 1.9 and 1.0, respectively. Therapeutic ratio of the compound in C-1498 system was 11, while those of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil were 3.3 and 2.5, respectively. 1-Hexylcarbamoyl-5-fluurouracil was also active against solid and ascites tumors by oral administration. It was markedly active against Nakahara-Fukuoka sarcoma, adenocarcinoma=755, and ascites sarcoma-180, and moderately active against Ehrlich ascites carcinoma. This compound had a wider tumor spectrum than 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil by oral administration.
A Hoshi, and
M Iigo, and
A Nakamura, and
M Yoshida, and
K Kuretani
October 1987,
European journal of cancer & clinical oncology,
A Hoshi, and
M Iigo, and
A Nakamura, and
M Yoshida, and
K Kuretani
June 1981,
Cancer treatment reviews,
A Hoshi, and
M Iigo, and
A Nakamura, and
M Yoshida, and
K Kuretani
March 1989,
European journal of cancer & clinical oncology,
A Hoshi, and
M Iigo, and
A Nakamura, and
M Yoshida, and
K Kuretani
December 1983,
Nihon Sanka Fujinka Gakkai zasshi,
A Hoshi, and
M Iigo, and
A Nakamura, and
M Yoshida, and
K Kuretani
September 1978,
Xenobiotica; the fate of foreign compounds in biological systems,
A Hoshi, and
M Iigo, and
A Nakamura, and
M Yoshida, and
K Kuretani
January 1980,
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
A Hoshi, and
M Iigo, and
A Nakamura, and
M Yoshida, and
K Kuretani
January 1988,
Chemotherapy,
A Hoshi, and
M Iigo, and
A Nakamura, and
M Yoshida, and
K Kuretani
November 1984,
Gan to kagaku ryoho. Cancer & chemotherapy,
A Hoshi, and
M Iigo, and
A Nakamura, and
M Yoshida, and
K Kuretani
August 1978,
Gan,
A Hoshi, and
M Iigo, and
A Nakamura, and
M Yoshida, and
K Kuretani
November 1962,
Cancer chemotherapy reports,
